{"id":62598,"date":"2026-02-05T01:06:01","date_gmt":"2026-02-05T00:06:01","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/veracyte-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026\/"},"modified":"2026-02-05T01:06:01","modified_gmt":"2026-02-05T00:06:01","slug":"veracyte-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/veracyte-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026\/","title":{"rendered":"Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026"},"content":{"rendered":"
\n

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc.<\/a> (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fourth quarter and full-year 2025 after the close of market on Wednesday, February 25, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe conference call will be webcast live from the company\u2019s website and will be available via the following link: https:\/\/edge.media-server.com\/mmc\/p\/motsphxv<\/a>. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company\u2019s website at https:\/\/investor.veracyte.com\/events-presentations<\/a>.<\/p>\n

\nThe conference call dial-ins can be accessed by registering via this link<\/a>.<\/p>\n

\nAbout Veracyte<\/b><\/p>\n

\nVeracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com<\/a> or follow us on LinkedIn<\/a> or X (Twitter)<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestors<\/b>
Shayla Gorman
\n
investors@veracyte.com<\/a>
(619) 393-1545<\/p>\n

\nMedia<\/b>
Karen Possemato
\n
media@veracyte.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fourth quarter and full-year 2025 after the close of market on Wednesday, February 25, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62598","6":"format-standard","7":"category-industry"},"yoast_head":"\nVeracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/veracyte-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fourth quarter and full-year 2025 after the close of market on Wednesday, February 25, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/veracyte-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-05T00:06:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260204343155\/en\/791654\/22\/Veracyte_RGB_LRG_H_registered.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026\",\"datePublished\":\"2026-02-05T00:06:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026\\\/\"},\"wordCount\":271,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260204343155\\\/en\\\/791654\\\/22\\\/Veracyte_RGB_LRG_H_registered.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026\\\/\",\"name\":\"Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260204343155\\\/en\\\/791654\\\/22\\\/Veracyte_RGB_LRG_H_registered.jpg\",\"datePublished\":\"2026-02-05T00:06:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260204343155\\\/en\\\/791654\\\/22\\\/Veracyte_RGB_LRG_H_registered.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260204343155\\\/en\\\/791654\\\/22\\\/Veracyte_RGB_LRG_H_registered.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/veracyte-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026\/","og_locale":"en_US","og_type":"article","og_title":"Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 - Pharma Trend","og_description":"SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fourth quarter and full-year 2025 after the close of market on Wednesday, February 25, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/veracyte-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026\/","og_site_name":"Pharma Trend","article_published_time":"2026-02-05T00:06:01+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260204343155\/en\/791654\/22\/Veracyte_RGB_LRG_H_registered.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/veracyte-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/veracyte-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026","datePublished":"2026-02-05T00:06:01+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/veracyte-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026\/"},"wordCount":271,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/veracyte-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260204343155\/en\/791654\/22\/Veracyte_RGB_LRG_H_registered.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/veracyte-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026\/","url":"https:\/\/pharma-trend.com\/en\/veracyte-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026\/","name":"Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/veracyte-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/veracyte-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260204343155\/en\/791654\/22\/Veracyte_RGB_LRG_H_registered.jpg","datePublished":"2026-02-05T00:06:01+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/veracyte-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/veracyte-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/veracyte-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260204343155\/en\/791654\/22\/Veracyte_RGB_LRG_H_registered.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260204343155\/en\/791654\/22\/Veracyte_RGB_LRG_H_registered.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/veracyte-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62598","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62598"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62598\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62598"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62598"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62598"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}